⌕
Travere Therapeutics · TVTX · Nasdaq
Tenet 43 · Weak
Compare
$51.10+2.82%At closeTenet 43 · Weak
$51.10+1.40 (+2.82%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Travere Therapeutics (TVTX) Stock

Travere Therapeutics (TVTX) closed at $51.10 on Nov 17, 2026; its Tenet Score is 43 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

29 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$51.10
Nov 17, 2026
Market cap
$4.8B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
22.59 – 68.73
low → high · as of close, Nov 16, 2026
Tenet Score
43/100
Weak · 340 Healthcare peers

Industry: Drugs

Travere Therapeutics Inc scores 43/100. Weak. Strongest on growth, value is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
0
Quality
53
Health
52
Growth
67

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthCGrowthCMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
211.2×
Sep 30, 2026 balance sheet
Outside the range we rank; ranked at the edge of the range.
P/S
7.3×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is under 5% of total assets.
Operating margin
−12.8%
fiscal 2025, before interest and tax
Net margin
−18.7%
TTM through Sep 30, 2026
Current ratio
3.00
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeo…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 110 US ETFs · top wrappers by weightSee all ETFs holding TVTX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Travere Therapeutics in?

Travere Therapeutics is in the Healthcare sector and the Drugs industry.

What is Travere Therapeutics' Tenet Score?

Travere Therapeutics' Tenet Score is 43 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.